New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Sanofi

SNY

Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.

Revenue
+13.9%
EPS
+8.21%
Free cash flow
+99.6%
Total debt
−11.2%

Quarter to September 2026, against a year earlier

46.62 0.56 +1.22%
Market cap
$111.3B
P/E
22.8×
Fwd P/E FY26e
—
Dividend yield
5.25%
F-score
7/9
ROIC
7.05%
Net debt / EBITDA
0.8×
Payout ratio
1.2×

What it owns vs. what it owes Q3 FY2026, Sep 30, 2026

It owes $13.8B more in debt than it holds in cash and short-term investments. Shareholders’ equity is 56.2% of the balance sheet. What is a balance sheet?

Sep 30, 2026 · total $150.0B

Owns

$111.7BLong-term assets
$31.4BOther short-term assets
$6.9BCash & short-term investments

Funded by

$84.3BShareholders’ equity
$45.0BOther liabilities
$20.7BDebt

Debt is 13.8% of the total; shareholders’ equity 56.2%.

Net debt has held near 9% of assets since Q4 FY25.

Total assetsNet debt (debt less cash)Net debt ÷ assets (right axis)
Assets and net debt, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Total assets$143.5B$149.8B$150.1B$150.0B
Net debt (debt less cash)$12.4B$14.8B$17.8B$13.8B
Net debt ÷ assets (right axis)8.6%9.9%11.9%9.2%
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Total current assets
35,019.09 35,303.95 36,650.63 38,221.26
Total non-current assets
108,448.10 114,535.30 113,407.40 111,739.10
Total Assets
143,467.20 149,839.30 150,058.10 149,960.30
Total current liabilities
32,069.53 35,121.36 37,125.01 34,261.82
Total non-current liabilities
30,264.95 29,111.36 32,047.50 31,398.13
Total liabilities
62,334.48 64,232.72 69,172.51 65,659.95
Common Equity (Total)
81,132.70 — 80,885.55 —
Shareholders Equity (Total)
81,132.70 85,606.57 80,885.55 84,300.39
Total Debt
21,032.73 21,323.52 25,198.03 20,651.24

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 5, 2026